{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/regulatory-strategy-keeping-end-mind#webpage",
"url": "https://www.fortrea.com/insights/regulatory-strategy-keeping-end-mind",
"name": "Regulatory strategy: keeping the end in mind",
"description": "This Fortrea white paper explores regulatory strategy in drug development and the importance of planning for successful market authorization from the earliest stages of development. The content focuses on regulatory strategy in drug development, Target Product Profiles (TPPs), Clinical Development Plans (CDPs), regulatory planning, risk identification, and market authorization readiness associated with product development programs. The white paper highlights factors related to development planning, regulatory requirements, quality, safety and efficacy considerations, submission readiness, and strategic decision-making affecting product advancement. Fortrea discusses regulatory and development perspectives designed to support proactive planning, strengthen development strategies, and reduce risks associated with regulatory milestones and submissions. By integrating Target Product Profiles, Clinical Development Plans, and regulatory planning approaches, the white paper provides insights into regulatory strategy in drug development and the planning considerations that support efficient progression from early development through market authorization."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Regulatory strategy: keeping the end in mind",
"item": "https://www.fortrea.com/insights/regulatory-strategy-keeping-end-mind"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/regulatory-strategy-keeping-end-mind#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/regulatory-strategy-keeping-end-mind#webpage"
},
"headline": "Regulatory Strategy for Drug Development Using TPPs & Clinical Development Plans | Fortrea White Paper",
"description": "This Fortrea white paper explores regulatory strategy in drug development and the importance of planning for successful market authorization from the earliest stages of development. The content focuses on regulatory strategy in drug development, Target Product Profiles (TPPs), Clinical Development Plans (CDPs), regulatory planning, risk identification, and market authorization readiness associated with product development programs. The white paper highlights factors related to development planning, regulatory requirements, quality, safety and efficacy considerations, submission readiness, and strategic decision-making affecting product advancement. Fortrea discusses regulatory and development perspectives designed to support proactive planning, strengthen development strategies, and reduce risks associated with regulatory milestones and submissions. By integrating Target Product Profiles, Clinical Development Plans, and regulatory planning approaches, the white paper provides insights into regulatory strategy in drug development and the planning considerations that support efficient progression from early development through market authorization.",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-11-05",
"dateModified": "2025-11-05",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-11/regulatory-strategy-keeping-the-end-in-mind.pdf",
"encodingFormat": "application/pdf"
}
}
]
}